Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-08
2007-05-08
Qazi, Sabiha N. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S137000, C546S133000, C546S268100
Reexamination Certificate
active
10454292
ABSTRACT:
Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.1]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.
REFERENCES:
patent: 4921982 (1990-05-01), Cohen et al.
patent: 4922901 (1990-05-01), Brooks et al.
patent: 4952229 (1990-08-01), Muir
patent: 4965074 (1990-10-01), Leeson
patent: 5164386 (1992-11-01), Cereda et al.
patent: 5187166 (1993-02-01), Kikuchi et al.
patent: 5210076 (1993-05-01), Berliner et al.
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5227391 (1993-07-01), Caldwell et al.
patent: 5242935 (1993-09-01), Lippiello et al.
patent: 5346906 (1994-09-01), Baker et al.
patent: 5488056 (1996-01-01), Bodick et al.
patent: 5510355 (1996-04-01), Bencherif et al.
patent: 5552138 (1996-09-01), Handelsman et al.
patent: 5559124 (1996-09-01), Bencherif et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5616716 (1997-04-01), Dull et al.
patent: 5663356 (1997-09-01), Ruecroft et al.
patent: 5672601 (1997-09-01), Cignarella
patent: 5702703 (1997-12-01), Schnepf et al.
patent: 5753222 (1998-05-01), Marrone et al.
patent: 5852038 (1998-12-01), Ito et al.
patent: 5852041 (1998-12-01), Cosford et al.
patent: 5853696 (1998-12-01), Elmaleh et al.
patent: 5969144 (1999-10-01), London et al.
patent: 6057446 (2000-05-01), Crooks et al.
patent: 6194193 (2001-02-01), Drahos et al.
patent: 6228806 (2001-05-01), Mehta
patent: 6310043 (2001-10-01), Bundle et al.
patent: 6311426 (2001-11-01), Mehta et al.
patent: 2001/0056084 (2001-12-01), Allgeier et al.
patent: 2003/0092700 (2003-05-01), Czollner et al.
patent: 0 297 858 (1989-04-01), None
patent: 0 588 917 (2000-11-01), None
patent: 2 295 387 (1996-05-01), None
patent: 363051398 (1988-03-01), None
patent: WO 94/08992 (1994-04-01), None
patent: WO 96/30372 (1996-10-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 97/30998 (1997-08-01), None
patent: WO 98/25619 (1998-06-01), None
patent: WO 99/03859 (1999-01-01), None
patent: WO 99/21834 (1999-05-01), None
patent: WO 99/62505 (1999-12-01), None
patent: WO 00/73431 (2000-12-01), None
patent: WO 01/36417 (2001-05-01), None
patent: WO 01/82978 (2001-11-01), None
patent: WO 02/15662 (2002-02-01), None
patent: WO 02/16355 (2002-02-01), None
patent: WO 02/16356 (2002-02-01), None
patent: WO 02/16357 (2002-02-01), None
patent: WO 02/16358 (2002-02-01), None
patent: WO 02/17358 (2002-02-01), None
Sivaman et al.; Influence of some plant phenolics on the activity of delta endotoxin ofBacillus thuringiensisvar.galleriaonHelithis armigera; Entomologia Experimentalis et applicata. 1992, vol. 63, pp. 243-248.
Kelada et al.; Toxicity of Three Chemical Insecticides in combination withBacillusspp. Against Mosquito Larvae; Insect Science Application ; 1988, vol. 9, pp. 229-230.
Asano et al.; Progidiosin Produced bySerratia marcescensenhances the insecticidal activity ofBacillus thuringlensisdelta endotoxin (CrylC) against common cutworm, Spodoptera litura; Journal of Pesticide Science; 1999, vol. 24, pp. 381-385.
Pramanik et al.; Persistence Toxicity ofBacillus thurigienstsVer Kurstaki in Combination with some Chemical Additives Under Field Condition; Environment and Ecology, vol. 18, No. 1, Mar. 2000, pp. 114-118.
Adler, L.E., et al., “Normalization by Nicotine of Deficient Auditory Sensory Gating to the Relatives of Schizophrenics,”Biol. Psychiatry, 32(7):607-616 (1992).
Arneric, S.P., et al., “Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator to the Potential Treatment of Alzheimer's Disease,”CNS Drug Rev., 1(1): 1-26 (1995).
Arneric, S.P., et al., “Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease,”Exp. Opin. Invest. Drugs, 5(1): 79-100 (1996).
Ashimori, A., et al., “Novel 1,4-Dihydropyridine Calcium Antagonists. I. Synthesis and Hypotensive Activity of 4-(Substituted Pyridyl)-1,4-dihydropyridine Derivatives,”Chem. Pharm. Bull., 38(9): 2446-2458 (1990).
Bannon, A.W., et al., “Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors,”Science, 279: 77-80 (1998).
Baron, J.A., “Cigarette smoking and Parkinson's disease,”Neurology, 36: 1490-1496 (1986).
Bencherif, M., and J. D. Schmitt, “Targeting Neuronal Nicotinic Receptors: a Path to New Therapies,”Current Drug Targets, 1(4): 349-357 (2002).
Bencherif, M., amd R.J. Lukas, “Ligand Binding and Functional Characterization of Muscarinic Acetylcholine Receptors on the TE671/RD Human Cell Line,”J. Pharmacol. Exp. Ther., 257(3): 946-953 (1991).
Bancherif, M., et al., “RJR-2403: A Nicotinic Agonist with CNS Selectively I: In Vitro Characterization,”J. Pharmacol. Exper. Therapeutics, 279(3): 1413-1421 (1996).
Bencherif M. and R.J. Lukas, “Differential Regulation of Nicotinic Acetylcholine Receptor Expression by Human TE67/RD Cells Following Second Messenger Modulation and Sodium Butyrate Treatments,”Mol. Cell. Neurosci., 2(1): 52-65 (1991).
Brioni, J.D., et al., “The Pharmacology of (—)-Nicotine and Novel Cholinergic Channel Modulators,”Adv. Pharmacol., 37: 153-214 (1997).
Burger, A., et al., “Some Derivatives of Tetrohydropyran as Potential Pharmacodynamic Agents,”J. Amer. Chem. Soc., 72: 5512-5515 (1950).
Calderon-Gonzalez, R., and R.F. Calderon-Sepulveda, “Tourette Syndrome Current Concepts,”Intern. Pediat., 8(2): 176-188 (1993).
Chen, Y., et al., “Asymmetric Synthesis VIII: Enantioselective Synthesis of (R) or (S) —Substituted Benzylamines Via Chiral Pinanone Ketimine Template,”Synth. Comm., 19(7&8): 1423-1430 (1989).
Cheng, Y., and W.H. Prusoff, “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50 Per Cent inhibition (I50) of an Enzymatic Reaction,”Biochem. Pharmacol., 22(23): 3099-3108 (1973).
Chiari, A., et al., “Sex Differences in Cholinergic Analgesia I: A Supplemental Nicotinic Mechanism in Normal Females,”Anesthesiology, 91(5): 1447-1454 (1999).
Clarke, P.B.S., et al., “Electrophysiological actions of nicotine on substantia nigra single units,”Br. J. Pharm., 85(4): 827-835 (1985).
Comins, D. L., and M.O. Killpack, “Lithiation of Methoxypyridines Directed by α-Amino Alkoxides,”J. Org. Chem., 55(1): 69-73 (1990).
Cosford, N.D.P., et al., “(S)-(—) 5- Ethynyl-3-(1-methyl-2-pyrrolidinyl) pyridine Maleate (SIB-1508Y): A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors,”J. Med. Chem., 39(17) : 3235-3237 (1996).
Damaj, M.I., et al., “Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist,”J. Pharmacol. Exp. Ther., 291(1): 390-398 (1999).
Davies, A.R.L., et al., “Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labeling α7-type neuronal nicotinic acetylcholine receptors,”Neuropharmacol., 38: 679-690 (1999).
Decina, P., et al., “Cigarette Smoking and Neuroleptic-Induced Parkinsonism,”Biol. Psychiatry, 28(6): 502-508 (1990).
De Kimpe, N.G., et al., “Synthesis of Cyclic Imines via Ethyleneteramethyldisilyl-Protected ω-Aminoimines, Application to the Synthesis of Alkaloids,”Tet. Lett.,
Bencherif Merouane
Bhatti Balwinder S.
Hawkins Gregory D.
Miller Craig Harrison
Qazi Sabiha N.
Targacept, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Pharmaceutical compositions and methods for effecting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and methods for effecting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and methods for effecting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823067